预亏股达嘉维康实控人方拟减持 2021上市募资6.4亿元

Core Viewpoint - The company Dajia Weikang (301126.SZ) announced a share reduction plan by its controlling shareholder's action partner, Changsha Tongjia Investment Management Partnership, which holds 4.77% of the company's total shares [1] Group 1: Share Reduction Announcement - Changsha Tongjia plans to reduce its holdings by up to 6,162,096 shares, representing 3.00% of the total share capital, within three months starting from March 10, 2026 [1] - As of the announcement date, Changsha Tongjia holds 9,800,000 shares of Dajia Weikang [1] Group 2: Financial Performance Forecast - Dajia Weikang expects to achieve an operating income of between 550 million to 600 million yuan for the year 2025, compared to 523.34 million yuan in the previous year [2] - The company anticipates a net loss attributable to shareholders of between 25 million to 30 million yuan for 2025, a significant decline from a profit of 2.66 million yuan in the previous year [2] - The expected net profit after deducting non-recurring gains and losses is also projected to be between -25 million to -30 million yuan, down from 2.56 million yuan in the previous year [2] Group 3: Initial Public Offering Details - Dajia Weikang was listed on the Shenzhen Stock Exchange's ChiNext board on December 7, 2021, with an initial public offering of 51.63 million shares at a price of 12.37 yuan per share [2] - The total funds raised amounted to 639 million yuan, with a net amount of 569 million yuan after deducting issuance costs, exceeding the original plan by 59.42 million yuan [2] - The funds are intended for chain pharmacy expansion, smart logistics center projects, and repayment of bank loans [2]

Hunan Dajiaweikang Pharmaceutical Industry -预亏股达嘉维康实控人方拟减持 2021上市募资6.4亿元 - Reportify